依托泊苷辅助治疗高危PFA室管膜瘤1例。

IF 0.9 4区医学 Q4 HEMATOLOGY

Journal of Pediatric Hematology/Oncology Pub Date : 2025-07-01 DOI:10.1097/MPH.0000000000003080

Jacob Silverman, Melissa Mégalli, Emilie Giguère, Sarah Elbaz, Melanie Letourneau, Catherine Achim, Cynthia Hawkins, William Legallou, Panagiota Giannakouros, Sébastien Perreault, Geneviève Legault, Eric Bouffet, Nada Jabado, Hallie Coltin, Louis Crevier, Samuele Renzi

{"title":"依托泊苷辅助治疗高危PFA室管膜瘤1例。","authors":"Jacob Silverman, Melissa Mégalli, Emilie Giguère, Sarah Elbaz, Melanie Letourneau, Catherine Achim, Cynthia Hawkins, William Legallou, Panagiota Giannakouros, Sébastien Perreault, Geneviève Legault, Eric Bouffet, Nada Jabado, Hallie Coltin, Louis Crevier, Samuele Renzi","doi":"10.1097/MPH.0000000000003080","DOIUrl":null,"url":null,"abstract":"Background: Ependymomas of the posterior fossa type A (PF-A) with a combined chromosome 1q gain and 6q loss are associated with an extremely high risk of recurrence and a very poor outcome.Observations: We report the case of a 4-year-old girl who received adjuvant oral etoposide for 1 year after conventional treatment (surgery and focal radiation). The patient remains in clinical and radiologic remission 2.5 years post-diagnosis.Conclusions: This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial.","PeriodicalId":16693,"journal":{"name":"Journal of Pediatric Hematology/Oncology","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adjuvant Etoposide for Very High-Risk PFA Ependymoma: A Case Report.\",\"authors\":\"Jacob Silverman, Melissa Mégalli, Emilie Giguère, Sarah Elbaz, Melanie Letourneau, Catherine Achim, Cynthia Hawkins, William Legallou, Panagiota Giannakouros, Sébastien Perreault, Geneviève Legault, Eric Bouffet, Nada Jabado, Hallie Coltin, Louis Crevier, Samuele Renzi\",\"doi\":\"10.1097/MPH.0000000000003080\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Ependymomas of the posterior fossa type A (PF-A) with a combined chromosome 1q gain and 6q loss are associated with an extremely high risk of recurrence and a very poor outcome.Observations: We report the case of a 4-year-old girl who received adjuvant oral etoposide for 1 year after conventional treatment (surgery and focal radiation). The patient remains in clinical and radiologic remission 2.5 years post-diagnosis.Conclusions: This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial.\",\"PeriodicalId\":16693,\"journal\":{\"name\":\"Journal of Pediatric Hematology/Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pediatric Hematology/Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MPH.0000000000003080\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Hematology/Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPH.0000000000003080","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：后窝A型室管膜瘤（PF-A）合并染色体1q增加和6q减少与极高的复发风险和非常差的预后相关。观察：我们报告一名4岁女孩在常规治疗（手术和局灶放疗）后接受辅助口服依托泊苷1年的病例。患者在诊断后2.5年仍处于临床和放射学缓解期。结论：口服依托泊苷治疗超高危6q丢失型PF-A室管膜瘤可考虑降低复发风险，有待临床试验进一步评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Adjuvant Etoposide for Very High-Risk PFA Ependymoma: A Case Report.

Background: Ependymomas of the posterior fossa type A (PF-A) with a combined chromosome 1q gain and 6q loss are associated with an extremely high risk of recurrence and a very poor outcome.

Observations: We report the case of a 4-year-old girl who received adjuvant oral etoposide for 1 year after conventional treatment (surgery and focal radiation). The patient remains in clinical and radiologic remission 2.5 years post-diagnosis.

Conclusions: This approach of using oral etoposide could be considered in ultra-high-risk 6q loss PF-A ependymoma to try and decrease the risk of relapse, awaiting further evaluation in a clinical trial.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pediatric Hematology/Oncology 医学-小儿科

CiteScore

1.90

自引率

8.30%

发文量

415

审稿时长

2.5 months

期刊介绍： Journal of Pediatric Hematology/Oncology (JPHO) reports on major advances in the diagnosis and treatment of cancer and blood diseases in children. The journal publishes original research, commentaries, historical insights, and clinical and laboratory observations.